ABSTRACT: Argininosuccinate synthetase 1 (ASS1) is a rate-limited enzyme in arginine biosynthesis. The oncogenic potential of ASS1 in terms of prognosis and cancer metastasis in arginine prototrophic gastric cancer (GC) remains unclear at present. We identify differentially expressed proteins in microdissected GC tumor cells relative to adjacent nontumor epithelia by isobaric mass tag for relative and absolute quantitation proteomics analysis. GC cells with stable expression or depletion of ASS1 were further analyzed to identify downstream molecules. We investigated their effects on chemoresistance and cell invasion in the presence or absence of arginine. ASS1 was highly expressed in GC and positively correlated with GC aggressiveness and poor outcome. Depletion of ASS1 led to inhibition of tumor growth and decreased cell invasion via induction of autophagy-lysosome machinery, resulting in degradation of active b-catenin, Snail, and Twist. Ectopic expression of ASS1 in GC cells reversed these effects and protected cancer cells from chemotherapy drug-induced apoptosis via activation of the AKTmammalian target of rapamycin signaling pathway. ASS1 contributes to GC progression by enhancing aggressive potential resulting from active b-catenin, Snail, and Twist accumulation. Our results propose that ASS1 might contribute to GC metastasis and support its utility as a prognostic predictor of
GC, we performed isobaric mass tags for relative and absolute quantitation (iTRAQ) labeling of GC specimens combined with liquid chromatography-mass spectrometry. As a result, argininosuccinate synthetase (ASS1) involved in amino acid metabolism was identified as a significantly up-regulated protein.
Arginine is a conditionally essential amino acid in humans but plays a vital role in protein synthesis, blood flow, and NO levels. The biosynthesis of urea, creatine, nucleotides, proline, and polyamines also require arginine (7) . ASS1 is a cytosolic rate-limiting enzyme of the urea cycle. It is mainly expressed in periportal hepatocytes of the liver but is expressed in most other body tissues and is involved in arginine synthesis (8) . Targeting extracellular arginine for degradation by the arginine-lowering drug PEGylated arginine deiminase is accompanied by profound autophagy and caspase-independent cell death in arginine auxotrophs (9) . Several studies have focused on the variable loss of ASS1 in several malignancies, including melanoma, hepatocellular carcinoma, glioblastoma, sarcomas, and lymphomas (8, (10) (11) (12) . In malignant ovarian, gastric, and colonic epithelia, high levels of ASS1 expression have been noted, compared with corresponding normal epithelial tissue (13) (14) (15) .
When cells encounter nutritional starvation, autophagy is the principal catabolic pathway to survival. During autophagy, cytosolic proteins and organelles are engulfed in a vesicle termed the autophagosome. Subsequently, microtubule-associated protein 1A/1B-light chain 3 is bound to phosphatidylethanolamine to compose LC3-phosphatidylethanolamine conjugate (LC3-II), which is recruited to the membrane of autophagosomes. Autophagosomes combine with lysosomes to develop autolysosomes, and intra-autophagosomal constituents are digested by lysosomal hydrolases along with LC3-II in the autolysosomal lumen (16) . However, extreme autophagy could be cytotoxic, leading to cell death (17, 18) . The coordination of autophagy is highly regulated, with inputs from the cellular environment through the phosphorylation of the Akt/mammalian target of rapamycin (mTOR) pathway by PI3K, which perceives nutrient levels and which, under nutrient-rich conditions, inhibits autophagy via phosphorylation of ULK1/2 (19) . Besides its role in organelle turnover, autophagy is involved in cell migration and epithelial-mesenchymal transition (EMT) (20, 21) to modulate metastasis.
The specific regulatory function of ASS1 in GC tumorigenesis, its clinical relevance, and downstream effectors have not been previously characterized. In the present study, we showed that ASS1 is frequently overexpressed in GC clinical samples and contributes to chemoresistance and metastasis.
MATERIALS AND METHODS

Subjects
All patients provided informed consent. A total of 120 patients (67 male, 53 female; median age, 66 yr; range 28-86 yr) diagnosed pathologically with GC at the Chang Gung Memorial Hospital from 2000 to 2005 were enlisted. Before surgery, no patient had received chemotherapy or radiotherapy, and all patients had undergone gastric resection (total gastrectomy, n = 35; subtotal gastrectomy, n = 85). Pathologic examination and further biochemical analyses were performed with informed consent. The study protocol was verified and approved by the Medical Ethics and Human Clinical Trial Committee of the Chang Gung Memorial Hospital. All patients were followed regularly at the outpatient department of our hospital every 3 mo in the first 2 yr, every 6 mo between years 3 and 5, and once a year thereafter.
Clinicopathological studies
Resected specimens were examined pathologically according to the criteria of the sixth edition of the American Joint Committee on Cancer classification system and the Japanese General Rules for GC Study (22) . Clinicopathological parameters included patient age and gender, tumor location and size, gross (Bormann's) tumor type, wall invasion, resection margin, histologic type, lymph node metastasis, vascular invasion, lymphatic invasion, and perineural invasion.
In-solution digestion and iTRAQ labeling after basic reverse-phase HPLC and shotgun proteomic identifications Total laser capture microdissection (LCM) proteins were reduced, alkylated, and digested with trypsin (Promega, Madison, WI, USA) at 37°C overnight. Peptide extracts were labeled with iTraq reagents (Applied Biosystems, Warrington, United Kingdom) and incubated for 1 h at 20°C. All labeled extracts were combined, mixed, and placed in a 2 3 100-mm Germini C18 column (Phenomenex, Torrance, CA, USA) coupled to a Waters HPLC system (Waters, Milford, MA, USA). Each fraction was dried at vacuum and resuspended in 0.3% formic acid for liquid chromatography-mass spectrometry analysis. NanoLC-nanoESi tandem mass spectrometry analysis was performed as previously described (23) . The resulting dataset was subjected to statistical analysis using the Trans-Proteomic Pipeline (http://tools.proteomecenter.org/TPP.php).
Immunoblot analysis
Western blot was performed as previously described (24) . The following primary antibodies were used at the recommended dilutions: anti-ASS1 (66036-1-Ig; ProteinTech, Rosemont, IL, USA), anti-LC3 (2775; Cell Signaling Technology, Danvers, MA, USA), anti-phospho-mTOR (pmTOR) (s2448) (2971; Cell Signaling Technology), anti-mTOR (2972; Cell Signaling Technology), anti-AKT1 (pS473) (epitomics, 2118-1), anti-active b-catenin (05-665; Millipore, Billerica, MA, USA), anti-b-tubulin (MAB1637; Chemicon, Temecula, CA, USA), anti-b-actin (MAB1501; Chemicon), anti-Twist (GTX127310; GeneTex, Irvine, CA, USA), anti-Snail (3879; Cell Signaling Technology), anti-lysosomalassociated membrane protein 1 (LAMP1) (2897-1; epitomics), anti-p53 (Sc-216; Santa Cruz Biotechnology, Dallas, TX, USA), anti-Bim (1036-1; epitomics), anti-active caspase 3 (1476-1; epitomics), anti-AKT1 (4691; Cell Signaling Technology), and anti-GAPDH (MAB374; Chemicon).
Immunohistochemistry
The following commercial primary antibodies were used at the recommended dilutions: anti-ASS1 (s, AV41366), anti-myosin 7B (14467-1-AP; ProteinTech), anti-karyopherin a 2 (10819-1-AP; ProteinTech), anti-Bystin (Sc-80001; Santa Cruz Biotechnology), anti-IFN-induced transmembrane protein (11714-1-AP; ProteinTech), anti-cell division cycle 5-like (Ab31779; Abcam, Cambridge, MA, USA), anti-DEK (16448-1-AP; ProteinTech), anti-heat shock protein 105 (Ab53107; Abcam), and anti-Radixin (epitomics, 2042-1). The avidin-biotin complex method and scoring formula were performed according to previously described procedures (25) .
RNA interference
Lentiviral pLKO, control short hairpin RNA (shRNA) specific for luciferase gene (shLuc) (TRCN0000072249, 59-CCGGGCGGT-TGCCAAGAGGTTCCATCTCGAGATGGAACCTCTTGGCA-ACCGCTTTTTG-39), and shRNAs ASS1-1 (TRCN0000045553, 59-CCGGCCATCCTTTACCATGCTCATTCTCGAGAATGA-GCATGGTAAAGGATGGTTTTTG-39), ASS1-2 (TRCN0000045554, 59-CCGGGCCTGAATTCTACAACCGGTTCTCGAGAACCGGT-TGTAGAATTCAGG CTTTTTG-39), LAMP1-1 (TRCN0000274915, 59-CCGGTGCTGCCTTCTCAGTGAACTACTCGAGTAGT-TCACTGAGAAGGCAGCATTTTTG-39), and LAMP1-2 (TRCN0000285264, 59-CCGGCGGCAATTCCTACAAGTGC-AACTCGAGTTGCACTTGTAGGAATTGCCGTTTTTG-39) were obtained from the National RNAi Core Facility at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica. Recombinant lentivirus carrying shRNA was produced according to previously described procedures (26) . We have performed target gene knockdown by 2 independent lentivirus-based shRNA clones to make pooled stable knock-down (KD) cells.
Real-time quantitative PCR
Real-time quantitative PCR (qPCR) was performed using the SYBR Green system as described previously (27) . Fluorescence emitted by SYBR green was observed using the ABI PRISM 7500 sequence detection system (Applied Biosystems). The following primers were used in this study: ASS1 
Cell lines and cultures
The human gastric carcinoma cell line AZ521 was kindly provided by Yu-Sun Chang from Chang Gung Molecular Medicine Research Center (Chang Gung University, Taoyuan, Taiwan) in 2011. The human gastric carcinoma cell line TMK-1 was kindly provided by Tsu-Chung Chang from Graduate Institute of Life Sciences (National Defense Medical Center, Taipei, Taiwan) in 2012. All cell lines were cultured in RMPI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Invitrogen), 100 IU/ml penicillin G, and 100 mg/ml streptomycin sulfate (Sigma-Aldrich, St. Louis, MO, USA) at 37°C in a humidified atmosphere containing 5% CO 2 . All cell lines were authenticated using short tandem repeat profiling. The last test date was 20 December 2013. Cells were maintained in culture for no longer than 4 mo and were routinely assayed for mycoplasma contamination.
Statistical analysis
A Mann-Whitney U or Fisher's exact test was used for betweengroup comparisons where appropriate, and the correlation between the results obtained with the two different methods was analyzed with Spearman's test. Follow-up studies on patients were performed until the time of manuscript preparation or patient death. Cancer-specific survival outcomes were evaluated by applying the Kaplan-Meier method for all patients except those who died from surgical complications. The log-rank test was used to compare the prognostic significance of individual variables on survival. A value of P , 0.05 was considered statistically significant.
RESULTS
Urea cycle enzymes are overexpressed in GC specimens
We used an iTRAQ labeling-based protein identification and quantification approach (Supplemental Fig. 1 ) with off-line basic reverse-phase HPLC (Supplemental Fig. 2 ) using the Thermo LTQ-orbitrap (Thermo Fisher Scientific, Waltham, MA, USA) mass spectrometer system to identify dysregulated proteins in 6 paired gastric adenocarcinoma tumors in relation to adjacent nontumor mucosa, captured by LCM (Supplemental Fig. 3 ). The nonredundant protein numbers identified and quantified are shown in Supplemental Table 1 . The candidates were separated into up-and downregulation groups based on dividing tumor intensity by nontumor intensity (T/N ratio), using 1.5-and 0.67-fold as the cutoff values (n = 415 down-regulated protein candidates; n = 251 up-regulated protein candidates). We examined the expression of 8 upregulated candidate proteins and 1 down-regulated candidate protein. Representative staining patterns for one paired tissue section per protein and scoring results for the nine candidates are depicted in Supplemental Fig. 4A and B, respectively. Comparison of the staining scores from tumor and nontumor counterparts revealed that the eight candidate genes are markedly overexpressed (.66% specimens) in tumor cells. Thus, consistent results were obtained from MS-based identification/ quantification and immunohistochemical validation experiments.
To establish the biologic networks affected by dysregulated proteins, 415 candidates showing increased expression were analyzed using MetaCore (v. 4.7) (28). The top-ranked up-regulated protein, ASS1, is involved in the amino acid metabolism pathway (P = 0.0004) (Supplemental Fig. 5A ). Urea cycle enzymes, including carbamoyl phosphate synthetase 1, OTC, ASS1, ASL, and ARG1, were significantly overexpressed in iTRAQ experiments. Clinical specimens were subjected to real-time qPCR (n = 120) to further validate the enhanced expression of urea cycle enzymes in GC. As shown in, all urea cycle enzymes were overexpressed in more than 50% of GC specimens (Supplemental Fig. 5B-F ).
High expression of ASS1 in GC is correlated with tumor aggressiveness and poor outcome
To verify enhanced expression of ASS1 in GC, immunohistochemistry (IHC) (n = 112) was performed on clinical specimens. The H score was analyzed in 112 patients. The mean score of tumor tissues was 1.51 6 0.95, which was significantly greater than that in paired adjacent mucosa (0.84 6 0.36). Elevated ASS1 was consistently detected in the majority of tumor regions, whereas nontumor areas contained relatively reduced ASS1 levels (Supplemental Fig. 6A ). Four pairs of representative cases subjected to IHC analysis are shown in Supplemental Fig. 6B . Strong staining of ASS1 was mostly detected in the cytosol of gastric tumor cells. In contrast, staining for ASS1 was absent or weak in nontumor gastric epithelial cells. Data from qPCR experiments revealed high ASS1 expression ($2-fold) in 80 of 120 (67%) GC tissues, compared with paired noncancerous tissues (P , 0.001) (Supplemental Figs. 5D and S6C). The enhanced expression of ASS1 was also supported by the GEO dataset of GC. According to the Cho (29) and D'Errico (30) dataset, ASS1 was significantly overexpressed in GC tumor parts compared with nontumor parts (Supplemental Fig. 7A, B) .
To determine the association between ASS1 expression and tumor characteristics, the T/N ratio of ASS1 evaluated using qPCR was analyzed in relation to clinicopathological parameters. The characteristics of the study patients (n = 120) are listed in Table 1 . The maximum diameter of tumor size was, on average, 5.6 cm (median, 5.2 cm; range, 0.3-20 cm). The locations of the tumors were 20% in the proximal third of the stomach, 24.1% in the middle third, 50.8% in the distal third, and 5% in the whole stomach. Histologic tumor types were intestinal in 35% of patients and diffuse in 65% of patients. According to the depth of wall invasion, mucosal and submucosal invasion (T1) was diagnosed in 20% of the patients, the muscle proper and subserosa invasion (T2) in 15% of the patients, serosa invasion (T3) in 49.2% of the patients, and invasion to adjacent organs (T4) in 15.8% of the patients. Lymph node metastasis was diagnosed in 72.5% of the cases. During surgery, peritoneal invasion was evident in 18.3% of the and in liver metastasis in 1.6% of the patients. Pathologic staging was distributed as follows: I, 25%; II, 8.3%; III, 39.1%; IV, 27.5%.
The expression of ASS1 in patients whose serosal surface of the gastric wall was invaded by cancer (T3 and T4 groups) was significantly higher than the no-invasion groups (T1 and T2) ( Fig. 1A ; Table 1 ). The data were also supported by the D'Errico (30) dataset in which the expression of ASS1 in T2 and T3 groups was significantly higher than the T1 and nontumor groups (Supplemental Fig. 7C ). In addition, patients with metastasis of the lymph nodes ( Fig. 1B ; Table 1 ) and those at more advanced pathologic stages ( Fig. 1C ; Table 1 ) of GC have prominently higher ASS1 expression.
Among the 120 patients, 65 died (56 due to gastric cancer progression, 2 due to surgical complications, and 7 due to noncancerous causes). The median follow-up duration for survivors (n = 55) was 83.1 mo (range, 64-137 mo). The cumulative 5-yr survival rate for the 120 patients was 53.4%. After dichotomization based on median ASS1 expression (T/N = 4.38), the ASS1-high group (n = 60) presented significantly shorter cumulative survival compared with the ASS1-low group (n = 60), determined using log-rank analysis ( Fig. 1D ; Table 1 ) (64.2 vs. 32.9%, log-rank P = 0.0001). Other factors that effectively predicted outcomes for cumulative survival analysis included gross type, tumor location, histologic type, tumor size, pathologic stage, depth of invasion, lymph node metastasis, peritoneal seeding, vascular invasion, distant metastasis, liver metastasis, lymphatic invasion, and perineural invasion (Table 1) . We conclude that ASS1 displays prognostic value for 5-yr cumulative survival. Our findings suggest a strong association between ASS1 expression and GC progression, supporting the utility of ASS1 as a useful prognostic marker for GC.
ASS1 depletion accelerates autophagy and inhibits cell proliferation and invasion in TMK-1 cells TMK-1 cells, which have abundant ASS1 expression endogenously, were transduced with two independent shRNAs stably targeting human ASS1, with the aim of exploring the oncogenic potential of ASS1 in GC. Stably knocked down ASS1 shRNA clearly led to reduced ASS1 expression (Fig. 2C ) accompanied by inhibited cell growth compared with that of cells transduced with shLuc control in vitro ( Fig. 2A ) and in vivo (Fig. 2B) . However, ASS1 KD did not induce apoptosis (data not shown). Because ASS1 is a key enzyme in urea cycle metabolism, we examined the possibility of autophagy. ASS1 KD decreased LC3-II expression. However, LC3-II levels were equivalent between ASS1 KD and shLuc control cells in the chloroquine (CQ) (an inhibitor of autolysosomal degradation) treatment group (Fig. 2C,  lanes 5, 6 vs. lanes 7, 8) . The data indicate that ASS1 KD accelerates degradation but does not affect production of intra-autophagosomal LC3-II. To further ascertain whether the increased degradation rate is due to accumulation of acidic vacuoles, cells were labeled with LysoTracker Red (Thermo Fisher Scientific), a dye that specifically stains acidophilic compartments. As shown in Fig. 2D , ASS1 depletion induced an enlargement of acidic vacuoles in number and size relative to control cells. By analyzing the fluorescence signal of a tandem monomeric red fluorescent protein (RFP)-green fluorescent protein (GFP)-LC3 reporter to further confirm whether ASS1 depletion activates autophagy through enhancing the autophagic flux (31), we found that GFP and RFP signals exhibited homogenous distribution throughout the shLuc control cells (Fig. 2E, upper left) . On the contrary, the RFP signal of ASS1-depleted cells was concentrated as a punctate structure (RFP+/GFP2, RFP-LC3 puncta) (Fig. 2E, upper right and lower panel) . These data indicate that ASS1 KD promotes the formation and maturation of autophagic vacuoles. Recent studies have reported that autophagy impairs cancer metastasis via degradation of EMT-related proteins, such as Snail and Twist (20, 32) . Because ASS1 depletion activated autophagy, ASS1-depleted cells displayed decreased invasive ability compared with control cells (Fig. 2F) . Stably ectopic expression of ASS1 inhibits autophagy via attenuation of lysosome activity and increases the invasive ability of AZ521 cells
To further confirm the role of ASS1 in autophagy regulation, ASS1-overexpressing AZ521 cells (Fig. 3A) , which have deficient ASS1 expression endogenously, were subjected to a monomeric RFP-GFP-LC3 tandem reporter assay. RFP-LC3 puncta and acidic vacuoles of ASS1-overexpressing cells were significantly reduced compared with those of vector control cells (Fig. 3A, B) . Ectopic expression of ASS1 inhibited the degradation, rather than affecting production of intra-autophagosomal LC3-II (Fig. 3C, lane 1 vs. lane 6) . Together, these data suggest that ASS1 attenuates the lysosomal degradation of intra-autophagosomal LC3-II to inhibit autophagy. ASS1-overexpressing cells displayed accelerated invasive ability compared with their control counterparts (Fig. 3D) . Figure 1 . ASS1 overexpression in human GC is correlated with patient prognosis. A) Scatter plot of ASS1 T/N ratio determined using qPCR according to depth of wall invasion (P , 0.001, T1-T2 vs. T3-T4). B) Scatter plot of ASS1 T/N ratio determined using qPCR according to lymph node metastasis (P , 0.001, N0 vs. N1-3). C) Scatter plot of ASS1 T/N ratio determined using qPCR according to pathologic stage (P , 0.001, stage I-II vs. stage III-IV). D) Kaplan-Meier survival curves of two groups of patients with GC defined based on an ASS1 expression cutoff value of 4.165 (median) established from the T/N ratio. The 5-yr survival rate of the lower ASS1 expression groups (n = 60) was significantly greater than that of the higher expression groups (n = 60; 64.2 vs. 32.9%; log-rank P = 0.0001). *P , 0.05, **P , 0.01, ***P , 0.001 (1-way ANOVA with Mann-Whitney test). Ectopic expression of ASS1 promotes resistance to chemotherapy drug-induced apoptosis through AKT-mTOR activation of AZ521 cells Recent studies have proposed that deregulated cancer cell metabolism improves cell survival due to increased energy production and metabolite synthesis (33) . To determine whether ASS1 protects GC cells against chemotherapy drug-induced death, ASS1-overexpressing cells were treated with different doses of cisplatin and doxorubicin, which are major chemotherapeutic agents for advanced gastric cancer. Cells overexpressing ASS1 displayed greater resistance to cisplatin and doxorubicin with higher half maximal inhibitory concentration values than control cells (Fig. 4A, B) . Consistently, ASS1-overexpressing cells contained significantly lower levels of g-H2AX, a marker for DNA double-strand breaks, after treatment with cisplatin compared with control cells (Fig. 4C) . To further investigate whether ASS1 accelerates metabolism to protect GC cells from chemotherapy drug-induced apoptosis, ASS1-overexpressing cells were treated with an mTOR inhibitor (Ku-0063794) or left untreated after cisplatin treatment, and the expression levels of apoptotic markers were analyzed. Overexpression of ASS1 resulted in elevated phosphorylation of AKT and mTOR, sensors of cellular amino acids, which was markedly inhibited upon Ku-0063794 treatment (Fig. 4D) . Because Ku-0063794 blocks mTORC1 and mTORC2 activities, phospho-AKT may also be attenuated due to mTORC2 inhibition. Consistent with these data, expression of the proapoptotic genes p53, bim, and active caspase-3 was decreased in ASS1-overexpressing cells treated with cisplatin. Proapoptotic gene levels were elevated, whereas the prosurvival signals phospho-mTOR and phospho-AKT were blocked by Ku-0063794. Our findings indicate that ASS1 increases metabolite synthesis, resulting in elevated survival signals that protect cells against chemotherapy drug-induced apoptosis.
ASS1 promotes cell invasion by stabilizing active b-catenin, Snail, and Twist through autophagy inhibition
To determine whether ASS1-induced cell invasion is dependent on autophagy regulation, ASS1-overexpressing cells were treated with HBSS containing normal levels of glucose and serum to induce autophagy followed by Transwell invasion assay. ASS1-induced cell invasion, mediated via increased active b-catenin, Snail, and Twist expression, was decreased by HBSS treatment, which triggered autophagy accompanied by degradation of the above EMT-associated proteins (Fig. 5A, B) . Similarly, control cells with lower invasive ability became highly invasive after CQ treatment, along with accumulation of active b-catenin (unphosphorylated), Snail, and Twist (Fig. 5C, D) . The data indicate that overexpression of ASS1-induced cell invasion as well as EMT-associated proteins resulted from autophagic inhibition. Conversely, ASS1-depleted cells with higher lysosomal activity showed lower invasive ability and EMT-related protein expression. Upon treatment of ASS1-depleted cells with CQ to inhibit autophagy, invasive ability and EMT-related protein expression were effectively rescued (Supplemental Fig. 8 ). ASS1-overexpressing AZ521 cells were cultured in RPMI 1640 without arginine followed by CQ treatment to determine the effect of arginine on autophagic regulation in ASS1-abundant GC. Distinct from the mechanism observed with conditioned medium, ASS1 overexpression induced significant autophagy inhibition through reducing LC3-II production in arginine-free conditions rather than decreasing lysosomal degradation (Figs.  2C and 5E ).
Arginine depletion reduces the invasive ability of ASS1-depleted human GC cells via activation of autophagy Conversely, autophagy was activated in ASS1-depleted cells via increased LC3-II production in arginine-free conditions (Fig. 6A) . To ascertain the role of arginine in ASS1-induced cell invasion, TMK-1 cells (displaying the most abundant endogenous ASS1 expression) were depleted of ASS1 and treated with arginine-free or conditioned medium followed by Transwell invasion assay. ASS1 depletion led to diminished cell invasion ability, compared with control cells, in conditioned medium. In arginine-free medium, depletion of ASS1 further suppressed matrix invasion ability to a significant extent compared with that in conditioned medium, whereas invasiveness of control cells remained relatively unaffected (Fig. 6B) . Consistent with invasion assay data, ASS1-depleted cells in conditioned medium displayed lower phospho-AKT and phospho-mTOR expression, resulting in autolysosomal degradation of active b-catenin, Snail, and Twist compared with control cells. In arginine-free medium, ASS1-depleted cells showed a further decrease in phospho-AKT and phospho-mTOR as well as EMT-related protein expression (Fig. 6C) . To determine whether the considerable decrease in EMT-related proteins is due to lysosomal degradation in arginine-free medium, cells were labeled with LysoTracker Red. ASS1-depleted cells in argininefree medium displayed a significant enlargement in the number and size of acidic vacuoles compared with those in conditioned medium (Supplemental Fig. 9 ). To further confirm the role of lysosomes in EMT-related protein degradation, vector-or ASS1-depleted TMK-1 cells were transduced with shRNAs targeting LAMP1, which is essential to maintain the structural integrity of the lysosomal compartment (shLAMP1), or luciferase KD control (shLuc) using the lentiviral delivery system. Depletion of LAMP1 was sufficient to restore the invasive properties of ASS1 knockdown cells owing to the accumulation of active b-catenin, Snail, and Twist (Fig. 6D, E) . Our data provide evidence of the mechanistic role of arginine depletion-induced autolysosomal degradation in regulation of cell invasion and EMTrelated protein degradation.
DISCUSSION
In the present study, we identify differentially expressed proteins in microdissected GC tumor cells relative to adjacent nontumor epithelia performed by LTQ-orbitrap mass spectrometer-based iTraq proteomics analysis. To our knowledge, this is the first and largest iTRAQ-based quantitative proteome dataset of microdissected GC clinical specimens. In the IHC validation experiment, comparison of the staining scores of tumor and nontumor counterparts revealed 8 candidate genes that were highly expressed in more than 75% of the tumor cells, indicating high isolation specificity by LCM and quantitative accuracy between tumor cells and nontumor mucosa. Our database supplies a dependable resource for the prospective investigation of novel GC biomarkers.
ASS1 was significantly overexpressed in GC compared with nontumor mucosa, as previously described (8). ASS1 (29) and D'Errico (30) gastric microarray datasets was higher than that in nontumor specimens, consistent with our data. The mechanisms underlying ASS1 overexpression in GC are unclear at present. Previous study has indicated that TNF-a and IL-1b control the expression of ASS1 in cancer cell lines (15) . Additionally, glutamine has been shown to induce ASS1. However, in contrast to cytokines that use NF-kB, glutamine regulates ASS1 with the Sp1 transcription factor (34) .
Cumulative overall survival analysis demonstrated that higher ASS1 expression is associated with poor outcome of patients with GC, in parallel with known clinical and pathologic factors for GC. Further analysis of the predictive potential of ASS1 expression supported its utility as a prognostic marker to identify aggressive GC, consistent with Kaplan-Meier data. Several reports have shown that loss of ASS1 expression is associated with tumor aggressiveness and worse prognoses in many tumor types, including myxofibrosarcoma (10), bladder cancers (12) , and osteosarcoma (35) . Unlike GC, the expression of ASS1 is silenced in these tumor types. Shortly before the preparation of this article, higher ASS1 expression was shown to be correlated with poor postoperative outcomes of patients with GC (13) . Although the survival data of the earlier study have no statistical significance, the findings lend support to the potential importance of regulation and function of ASS1 in GC.
Prevalent cancer therapies, such as chemotherapy and radiation, lead to autophagy within tumor cells (36) . Tumor autophagy is even altered in patients subjected to chemotherapy drugs, elevating the question of whether diminishing inadvertently the autophagy of drugs would enhance the therapeutic effect. Previous studies have shown that the low level of ASS1 expressed in arginine-auxotrophic tumors, such as ovarian cancer and hepatocellular carcinoma, is associated with cisplatin resistance (37, 38) . The role of ASS1 on chemotherapy drug resistance in arginine prototrophic cancer is unclear. Our experiments showed that ectopic expression of ASS1 protects human GC cells from chemotherapy drug-induced apoptosis through AKT and mTOR activation, thereby inhibiting the autophagy process. Therefore, down-regulation of ASS1 may present a potential strategy to counter GC chemoresistance.
To satisfy tumor bioenergenesis and biosynthesis, cancer cells adjust their metabolic pathway. In arginine biosynthesis, ASS1 is a rate-limited enzyme with reduced abundance in many solid tumors, such as melanoma, hepatocellular carcinoma, and breast cancer (39) , making tumor cells sensitive to external arginine depletion by PEGylated arginine deiminase. The molecular mechanisms underlying the oncogenic role of ASS1 in GC are unclear at present. To our knowledge, this is the first study to propose that ASS1 is capable of inhibiting autophagy of GC cells, resulting in elevation of invasion potential via active b-catenin, Snail, and Twist accumulation. Our results indicate a significant role of ASS1 in GC metastasis.
In summary, ASS1-enhanced cell invasion ability via inhibition of lysosome activity as well as autophagy resulted in accumulation of active b-catenin, Snail, and Twist. Furthermore, ASS1 protects GC cells from chemotherapy drug-induced apoptosis by enhancing the prosurvival signals pAKT and pmTOR (Fig. 6F ). Significant overexpression of ASS1 in GC suggests a critical role of the protein in disease development and progression to malignancy. ASS1 may present a useful prognostic tumor marker to predict survival and metastasis of patients with GC. Our findings provide evidence supporting the utility of ASS1 as a potential therapeutic target to counteract GC chemoresistance and metastasis.
